BOTHELL, Wash., April 15, 2021 /PRNewswire/ — BioLife Solutions, Inc. (NASDAQ: BLFS) (“BioLife” or the “Firm”), a number one developer and provider of a portfolio of class-defining bioproduction services for cell and gene therapies, at this time introduced that it has launched a brand new line of excessive capability managed price freezers (HCRF), with an preliminary cargo to a number one cell remedy firm. The freezer can be a essential part on this buyer’s chilly chain administration of a number of allogeneic cell therapies in improvement.
Todd Berard, BioLife’s Chief Advertising and marketing Officer, commented, “This product launch expands our Cryogenic Freezer Platform with excessive capability managed price freezers designed particularly to satisfy the wants of cell and gene remedy builders. We’re more than happy to assist this and several other different pending prospects by offering a essential chilly chain administration platform to guard their excessive worth biologic supplies that require exact management of the essential freezing course of and subsequent frozen storage.”
Key options and advantages of the Excessive Capability Price Freezer product line embody:
- Giant Quantity Freezing – Capability to freeze as much as a number of thousand cryovials or a number of hundred cryobags in cassettes in a single run, saving time and making certain consistency in freeze runs.
- High quality Assurance Information Administration – Capability to chart samples by chamber and program temperature to make sure freeze run consistency.
- Contact Display Controller – Contains 6 pre-set run applications and the choice to create customized freeze run profiles.
- A number of Fan and Probe Design – Ensures uniform temperature throughout the payload cavity.
- Precision Management – Temperature vary of -180 to + 50°C, with freeze charges of 0.01 to 99.9°C per minute.
- Modern Racking Methods – Permits versatile and environment friendly payload loading and storage.
- Decreased working price – Much less liquid nitrogen required vs. competing merchandise.
Roderick de Greef, Chief Monetary and Working Officer at BioLife Options, remarked, “The crew at CBS has labored onerous to finish the design, manufacturing and validation of this new and differentiated managed price freezer. We’ve mentioned that new product introductions are key to driving gross margin enlargement inside our freezer line, and this can be a step towards that aim, as we anticipate unit gross margins on this product household within the mid to excessive 50% vary, with common promoting costs within the $450,000 to $750,000 vary.
About BioLife Options
BioLife Options is a number one provider of class-defining cell and gene remedy bioproduction instruments and providers. Our instruments portfolio contains our proprietary CryoStor® freeze media and HypoThermosol® delivery and storage media, ThawSTAR® household of automated, water-free thawing merchandise, evo® chilly chain administration system, Custom Biogenic Systems excessive capability storage freezers and SciSafe biologic storage providers. For extra info, please go to www.biolifesolutions.com, and observe BioLife on Twitter.
Cautions Relating to Ahead Trying Statements
Aside from historic info contained herein, this press launch accommodates forward-looking statements throughout the which means of the Non-public Securities Litigation Reform Act of 1995. These forward-looking statements embody, however will not be restricted to, statements in regards to the anticipated efficiency of the Firm’s excessive capability managed price freezers, the demand for and affect of the excessive capability managed price freezers for the Firm’s prospects, the typical sale worth and gross margin of the excessive capability managed price freezers, and the affect on gross margin of the excessive capability managed price freezers on the Firm’s freezer line of merchandise typically. All statements aside from statements of historic reality are statements that might be deemed forward-looking statements. These statements are based mostly on administration’s present expectations and beliefs and are topic to numerous dangers, uncertainties and assumptions that would trigger precise outcomes to vary materially from these described within the forward-looking statements, together with amongst different issues, uncertainty relating to surprising prices related to the manufacturing or scaling up of manufacturing of the excessive capability managed price freezers, market adoption of the excessive capability managed price freezers particularly or the corporate’s suite of merchandise typically, the power of the corporate to implement its enterprise technique, uncertainty relating to third-party market projections, market volatility, competitors, litigation, the affect of the COVID-19 pandemic, and people different components described in our threat components set forth in our filings with the Securities and Alternate Fee once in a while, together with our Annual Report on Type 10-Okay, Quarterly Reviews on Type 10-Q and Present Reviews on Type 8-Okay. We undertake no obligation to replace the forward-looking statements contained herein or to mirror occasions or circumstances occurring after the date hereof, aside from as could also be required by relevant regulation.
Media & Investor Relations
Roderick de Greef
Chief Monetary Officer & Chief Working Officer
View unique content material to obtain multimedia:http://www.prnewswire.com/news-releases/biolife-solutions-launches-new-high-capacity-controlled-rate-freezer-line-with-first-shipment-to-a-leading-cell-therapy-developer-301269417.html
SOURCE BioLife Options, Inc.
— to www.khq.com